Rchr
J-GLOBAL ID:201601016572155134   Update date: Mar. 24, 2024

Sugimoto Naoshi

Sugimoto Naoshi
Affiliation and department:
Research field  (6): Biomaterials ,  Biomedical engineering ,  Hematology and oncology ,  Hematology and oncology ,  Hematology and oncology ,  Hematology and oncology
Research keywords  (3): regenerative medicine ,  immunology ,  hematology
Research theme for competitive and other funds  (3):
  • 2021 - 2026 Elucidating the fundamental mechanism of platelet biogenesis and its medical application
  • 2021 - 2024 Elucidation of the NK cell immune escape mechanism using iPS cell-derived platelets and development of treatment
  • 2015 - 2019 The role of the nucleic acid sensor molecule DHX29 in hematopoietic cell immune responses and hematopoietic tumors
Papers (42):
  • Si Jing Chen, Kazuya Hashimoto, Kosuke Fujio, Karin Hayashi, Sudip Kumar Paul, Akinori Yuzuriha, Wei-Yin Qiu, Emiri Nakamura, Maria Alejandra Kanashiro, Mio Kabata, et al. A let-7 microRNA-RALB axis links the immune properties of iPSC-derived megakaryocytes with platelet producibility. Nature Communications. 2024. 15. 1
  • Charlotte Flahou, Tatsuya Morishima, Natsumi Higashi, Yoshikazu Hayashi, Huaigeng Xu, Bo Wang, Chaoqi Zhang, Atsushi Ninomiya, Wei-Yin Qiu, Akinori Yuzuriha, et al. Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells. Biochemical and biophysical research communications. 2023. 662. 76-83
  • Naoshi Sugimoto, Sou Nakamura, Shin Shimizu, Akiko Shigemasa, Junya Kanda, Nobuki Matsuyama, Mitsunobu Tanaka, Tomoya Hayashi, Akihiro Fuchizaki, Masayuki Nogawa, et al. Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial. Blood advances. 2022. 6. 23. 6056-6069
  • Naoshi Sugimoto, Junya Kanda, Sou Nakamura, Toshiyuki Kitano, Masakatsu Hishizawa, Tadakazu Kondo, Shin Shimizu, Akiko Shigemasa, Hideyo Hirai, Yasuyuki Arai, et al. iPLAT1: The first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study. Blood. 2022. 140. 22. 2398-2402
  • Masamitsu Sone, Sou Nakamura, Sachiko Umeda, Harumi Ginya, Motohiko Oshima, Maria Alejandra Kanashiro, Sudip Kumar Paul, Kanae Hashimoto, Emiri Nakamura, Yasuo Harada, et al. Silencing of p53 and CDKN1A establishes sustainable immortalized megakaryocyte progenitor cells from human iPSCs. Stem Cell Reports. 2021. 16. 12. 2861-2870
more...
MISC (46):
Books (1):
  • ハリソン内科学
    2017
Lectures and oral presentations  (24):
  • iPS細胞技術を用いた造血システムの再構成と治療への応用
    (第81回日本血液学会学術集会 2019)
  • iPS細胞を用いた血小板製剤の臨床応用の展望
    (第43回日本血液事業学会 2019)
  • Turbulence enables large scale production and clinical application of iPS cell-derived platelets
    (2019)
  • iPS血小板の開発と臨床応用
    (第18回先端医療フォーラム 2019)
  • iPS細胞由来血小板製剤の開発と将来
    (第50回日赤薬剤師会血液センター研究会 2019)
more...
Association Membership(s) (4):
THE JAPANESE SOCIETY OF HEMATOLOGY ,  THE JAPANESE SOCIETY OF INTERNAL MEDICINE ,  THE JAPANESE SOCIETY FOR IMMUNOLOGY ,  日本再生医療学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page